Advertisement

ADVERTISEMENT

Chadi Nabhan, MD, MBA, FACP

Column
Prognostication and Treatment of Diffuse Large B-cell Lymphoma
12/05/2018
Chadi Nabhan, MD, MBA, FACP
Journal of Clinical Pathways is pleased to present a new section called “CME Corner,” which will highlight, when available, relevant continuing medical education (CME) opportunities deemed to be of use to readers....
Journal of Clinical Pathways is pleased to present a new section called “CME Corner,” which will highlight, when available, relevant continuing medical education (CME) opportunities deemed to be of use to readers....
...
12/05/2018
Journal of Clinical Pathways
Research Reports
Community Oncologists` Perception and Acceptance of Biosimilars in Oncology
09/13/2018
Chadi Nabhan, MD, MBA, FACP
Yolaine Jeune-Smith, PhD
Amy Valley, PharmD
Bruce A Feinberg, DO
Abstract: Biosimilars are hypothesized to contribute to lowering health care costs by entering the market at a discounted price compared with their reference biologics. Until recently, only filgrastim biosimilars...
Abstract: Biosimilars are hypothesized to contribute to lowering health care costs by entering the market at a discounted price compared with their reference biologics. Until recently, only filgrastim biosimilars...
...
09/13/2018
Journal of Clinical Pathways
Counterpoint
CAR-T Therapies: Placing Patient Safety First
08/22/2018
Chadi Nabhan, MD, MBA, FACP
Bruce A Feinberg, DO
The commercial success and ability of eligible patients to receive chimeric antigen receptor T-cell (CAR-T) therapies depend on optimizing the logistics of delivering this transformational treatment platform. One...
The commercial success and ability of eligible patients to receive chimeric antigen receptor T-cell (CAR-T) therapies depend on optimizing the logistics of delivering this transformational treatment platform. One...
The...
08/22/2018
Journal of Clinical Pathways
Research Reports
Community Oncologists‚ Perception and Adaptability to Emerging Chimeric Antigen T-Cell Therapy
10/16/2017
Chadi Nabhan, MD, MBA, FACP
Yolaine Jeune-Smith, PhD
Peter Klinefelter, BA
Jennifer Fillman, MBA
Bruce A. Feinberg, DO
Abstract: The Oncologic Drugs Advisory Committee recently voted 10-0 recommending to the Food and Drug Administration (FDA) the approval of the first chimeric antigen receptor T (CAR-T) therapy. We sought to better...
Abstract: The Oncologic Drugs Advisory Committee recently voted 10-0 recommending to the Food and Drug Administration (FDA) the approval of the first chimeric antigen receptor T (CAR-T) therapy. We sought to better...
...
10/16/2017
Journal of Clinical Pathways
Feature
Positioning CAR-T Therapy Into Clinical Pathways for Non-Hodgkin B-Cell Lymphoma and Beyond
03/23/2017
Chadi Nabhan, MD, MBA, FACP
Sandeep Parsad, PharmD, BCOP
Bruce A Feinberg, DO
Abstract: Enthusiasm for immunotherapy has spread throughout the oncology community in recent years, as therapies harnessing the body’s ability to fight cancers have offered the potential for remission and even cure...
Abstract: Enthusiasm for immunotherapy has spread throughout the oncology community in recent years, as therapies harnessing the body’s ability to fight cancers have offered the potential for remission and even cure...
...
03/23/2017
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

September 18 ⁠–⁠ September 20
September 21 ⁠–⁠ September 22
AMP Europe
September 30 ⁠–⁠ October 2
October 1 ⁠–⁠ October 2
SAWC Fall
October 2 ⁠–⁠ October 5
October 5 ⁠–⁠ October 6
SMASH
October 14 ⁠–⁠ October 16
Lymphoma, Leukemia, and Myeloma
October 16 ⁠–⁠ October 19
October 19 ⁠–⁠ October 20
October 26 ⁠–⁠ October 27
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use